Skip to content

Research and Validation of a Big Data-Driven Intelligent Decision-Making System for Hemodialysis

Research and Validation of a Big Data-Driven Intelligent Decision-Making System for Hemodialysis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07466329
Enrollment
778
Registered
2026-03-12
Start date
2011-01-01
Completion date
2025-09-30
Last updated
2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ESRD (End Stage Renal Disease)

Keywords

End-Stage Renal Disease, Maintenance Hemodialysis

Brief summary

Objectives and Scope:This observational study aims to leverage real-world data from Huashan Hospital to develop an AI-driven intelligent decision-making system for assessing dialysis adequacy in maintenance hemodialysis (MHD) patients, and to analyze early warning factors contributing to inadequate dialysis. Core Research Question:Can an AI-based early warning and diagnostic model, built on multidimensional big data, identify the risk of inadequate hemodialysis at an ultra-early stage and accurately diagnose composite complications such as cardiovascular and cerebrovascular diseases? Methodology:The study will conduct a retrospective analysis of adult MHD patients treated at Huashan Hospital between January 2011 and September 2025. The dataset encompasses multidimensional variables, including sociodemographics, treatment parameters, laboratory indicators, metabolomics, and physical functions. Utilizing Dynamic Network Biomarkers (DNB) technology to screen for early warning markers, combined with artificial intelligence algorithms such as Neural Networks and Support Vector Machines (SVM), the study will construct two primary models: "Ultra-early Warning" and "Disease State Diagnosis." These models are designed to provide clinical decision support for precise interventions.

Detailed description

Research Background:End-stage renal disease (ESRD) represents the terminal stage of chronic kidney disease (CKD) progression. By 2020, the global ESRD population exceeded 12 million, with China accounting for nearly 30%, the highest in the world. Renal replacement therapy (RRT), including hemodialysis (HD), peritoneal dialysis (PD), and kidney transplantation, is the primary treatment for ESRD. Over 3.5 million patients worldwide receive maintenance dialysis, 90% of whom undergo HD. According to the Chinese National Renal Data System (CNRDS), the total number of dialysis patients in China approached 1 million in 2022, with maintenance hemodialysis (MHD) patients reaching 840,000-a 3.5-fold increase from 2012. Addressing the rapid growth in dialysis demand by improving medical quality and promoting social reintegration has become a global healthcare priority.Dialysis adequacy is a critical survival indicator for MHD patients. Currently, clinical practice relies on the Urea Reduction Ratio (URR) and Kt/V to assess adequacy. However, the 2002 HEMO study demonstrated that high-flux dialysis based on Kt/V did not improve survival rates. Consequently, existing metrics are criticized for failing to reflect the clearance of middle-molecule toxins and lacking a direct correlation with clinical outcomes, quality of life, and long-term prognosis. Identifying which indicators and computational models best assess dialysis adequacy remains an unresolved challenge in nephrology.Recently, advancements in Artificial Intelligence (AI) have offered new research avenues for assessing dialysis adequacy. Since 2005, studies using Artificial Neural Networks (ANN) and various machine learning (ML) models-including Decision Trees (DT), Random Forest (RF), Support Vector Machines (SVM), and Extreme Gradient Boosting (XGBoost)-have demonstrated superior predictive performance (AUROC up to 0.874) compared to traditional linear regression and formulas (e.g., Smye, Daugirdas). Despite this progress, existing studies often lack comprehensive variables such as dietary nutrition, neuropsychiatric status, and physical function. Furthermore, most current models are "diagnostic" in nature-identifying differences between stable "normal" and "diseased" states-making them suitable for diagnosis but insufficient for early intervention.Therefore, this retrospective study leverages real-world data (RWD) from Huashan Hospital to identify early warning factors for inadequate dialysis. The investigators aim to construct an "Ultra-early AI Warning Model" and an "AI Diagnostic Model" to form an Intelligent Decision-Making System for Hemodialysis, providing precise clinical intervention recommendations.

Interventions

None listed

Sponsors

Huashan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients undergoing long-term maintenance hemodialysis with a dialysis vintage of at least 3 months. * Aged between 18 and 90 years. * Possess relatively comprehensive hemodialysis records maintained within this center.

Exclusion criteria

* Patients with significantly incomplete dialysis-related data. * Patients with poor compliance during dialysis or those receiving palliative dialysis. * Other conditions deemed unsuitable by the investigator.

Design outcomes

Primary

MeasureTime frameDescription
Cardiovascular and Cerebrovascular Diseases (CCVD)15 years (From January 2011 to September 2025)Clinicians diagnose these conditions based on the American Heart Association (AHA) professional guidelines and diagnostic criteria.

Secondary

MeasureTime frameDescription
Composite Complications15 years (From January 2011 to September 2025)Composite outcome including Protein-Energy Wasting (PEW), Mineral and Bone Disorder (MBD), anemia, infection, and tumors. PEW is diagnosed based on the International Society of Renal Nutrition and Metabolism (ISRNM) criteria. MBD and anemia are diagnosed following the clinical guidelines from Kidney Disease: Improving Global Outcomes (KDIGO), the Japanese Society for Dialysis Therapy (JSDT), or the Japanese Society of Nephrology (JSN). Severe infection is diagnosed according to the Systemic Inflammatory Response Syndrome (SIRS) criteria. Tumors are identified based on clinical diagnoses by physicians.

Countries

China

Contacts

PRINCIPAL_INVESTIGATORJing Chen

Huashan Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026